1
|
Zhou L, Tian M, Zhang B, Cao X, Huo X, Yang F, Cao P, Feng L, Ma X, Tian X. Lysosome targeting fluorescent probe for NAAA imaging and its applications in the drug development for anti-inflammatory. Int J Biol Macromol 2024; 263:130307. [PMID: 38382784 DOI: 10.1016/j.ijbiomac.2024.130307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 02/04/2024] [Accepted: 02/18/2024] [Indexed: 02/23/2024]
Abstract
N-acylethanolamine acid amidase (NAAA) is a nucleophilic lysosomal cysteine hydrolase, which primarily mediates the hydrolytic inactivation of endogenous palmitoylethanolamide (PEA), which further influences the inflammatory process by regulating peroxisome proliferator-activated receptor-α (PPAR-α). Herein, a novel lysosome (Lyso)-targeting fluorescent probe (i.e., PMBD) was designed and synthesized for detecting endogenous NAAA selectively and sensitively, allowing real-time visual monitoring of endogenous NAAA in living cells. Moreover, PMBD can target Lyso with a high colocalization in Lyso Tracker. Finally, a high-throughput assay method for NAAA inhibitor screening was established using PMBD, and the NAAA-inhibitory effects of 42 anti-inflammatory Traditional Chinese medicines were evaluated. A novel potent inhibitor of NAAA, ellagic acid, was isolated from Cornus officinalis, which can suppress LPS-induced iNOS upregulation and NO production in RAW264.7 cells that display anti-inflammatory activities. PMBD, a novel Lyso-targeting fluorescent probe for visually imaging NAAA, could serve as a useful molecular tool for exploring the physiological functions of NAAA and drug development based on NAAA-related diseases.
Collapse
Affiliation(s)
- Limin Zhou
- Second Affiliated Hospital, Dalian Medical University, Dalian 116023, China; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China
| | - Manman Tian
- Second Affiliated Hospital, Dalian Medical University, Dalian 116023, China
| | - Baojing Zhang
- Second Affiliated Hospital, Dalian Medical University, Dalian 116023, China
| | - Xudong Cao
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China
| | - Xiaokui Huo
- Second Affiliated Hospital, Dalian Medical University, Dalian 116023, China
| | - Fangyu Yang
- General Hospital of Northern Theater Command, Department of Neurosurgery, Shenyang, China
| | - Peng Cao
- General Hospital of Northern Theater Command, Department of Neurosurgery, Shenyang, China.
| | - Lei Feng
- Second Affiliated Hospital, Dalian Medical University, Dalian 116023, China; School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China.
| | - Xiaochi Ma
- Second Affiliated Hospital, Dalian Medical University, Dalian 116023, China
| | - Xiangge Tian
- Second Affiliated Hospital, Dalian Medical University, Dalian 116023, China.
| |
Collapse
|
2
|
Greco R, Demartini C, Zanaboni AM, Francavilla M, De Icco R, Ahmad L, Tassorelli C. The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain. Headache 2022; 62:227-240. [PMID: 35179780 DOI: 10.1111/head.14267] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 12/10/2021] [Accepted: 12/23/2021] [Indexed: 12/13/2022]
Abstract
BACKGROUND Migraine is a complex and highly disabling neurological disease whose treatment remains challenging in many patients, even after the recent advent of the first specific-preventive drugs, namely monoclonal antibodies that target calcitonin gene-related peptide. For this reason, headache researchers are actively searching for new therapeutic targets. Cannabis has been proposed for migraine treatment, but controlled clinical studies are lacking. A major advance in cannabinoid research has been the discovery of the endocannabinoid system (ECS), which consists of receptors CB1 and CB2; their endogenous ligands, such as N-arachidonoylethanolamine; and the enzymes that catalyze endocannabinoid biosynthesis or degradation. Preclinical and clinical findings suggest a possible role for endocannabinoids and related lipids, such as palmitoylethanolamide (PEA), in migraine-related pain treatment. In animal models of migraine-related pain, endocannabinoid tone modulation via inhibition of endocannabinoid-catabolizing enzymes has been a particular focus of research. METHODS To conduct a narrative review of available data on the possible effects of cannabis, endocannabinoids, and other lipids in migraine-related pain, relevant key words were used to search the PubMed/MEDLINE database for basic and clinical studies. RESULTS Endocannabinoids and PEA seem to reduce trigeminal nociception by interacting with many pathways associated with migraine, suggesting a potential synergistic or similar effect. CONCLUSIONS Modulation of the metabolic pathways of the ECS may be a basis for new migraine treatments. The multiplicity of options and the wealth of data already obtained in animal models underscore the importance of further advancing research in this area. Multiple molecules related to the ECS or to allosteric modulation of CB1 receptors have emerged as potential therapeutic targets in migraine-related pain. The complexity of the ECS calls for accurate biochemical and pharmacological characterization of any new compounds undergoing testing and development.
Collapse
Affiliation(s)
- Rosaria Greco
- Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy
| | - Chiara Demartini
- Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy
| | - Anna Maria Zanaboni
- Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.,Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | - Miriam Francavilla
- Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy
| | - Roberto De Icco
- Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.,Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | - Lara Ahmad
- Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.,Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | - Cristina Tassorelli
- Headache Science & Neurorehabilitation Center, IRCCS Mondino Foundation, Pavia, Italy.,Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| |
Collapse
|
3
|
Xie X, Li Y, Xu S, Zhou P, Yang L, Xu Y, Qiu Y, Yang Y, Li Y. Genetic Blockade of NAAA Cell-specifically Regulates Fatty Acid Ethanolamides (FAEs) Metabolism and Inflammatory Responses. Front Pharmacol 2022; 12:817603. [PMID: 35069223 PMCID: PMC8777083 DOI: 10.3389/fphar.2021.817603] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Accepted: 12/16/2021] [Indexed: 12/28/2022] Open
Abstract
N-Acylethanolamine acid amidase (NAAA) is a lysosomal enzyme responsible for the hydrolysis of fatty acid ethanolamides (FAEs). However, the role of NAAA in FAEs metabolism and regulation of pain and inflammation remains mostly unknown. Here, we generated NAAA-deficient (NAAA-/-) mice using CRISPR-Cas9 technique, and found that deletion of NAAA increased PEA and AEA levels in bone marrow (BM) and macrophages, and elevated AEA levels in lungs. Unexpectedly, genetic blockade of NAAA caused moderately effective anti-inflammatory effects in lipopolysaccharides (LPS)-induced acute lung injury (ALI), and poor analgesic effects in carrageenan-induced hyperalgesia and sciatic nerve injury (SNI)-induced mechanical allodynia. These data contrasted with acute (single dose) or chronic NAAA inhibition by F96, which produced marked anti-inflammation and analgesia in these models. BM chimera experiments indicated that these phenotypes were associated with the absence of NAAA in non-BM cells, whereas deletion of NAAA in BM or BM-derived cells in rodent models resulted in potent analgesic and anti-inflammatory phenotypes. When combined, current study suggested that genetic blockade of NAAA regulated FAEs metabolism and inflammatory responses in a cell-specifical manner.
Collapse
Affiliation(s)
- Xiaohua Xie
- Department of Pediatrics, The First Affiliated Hospital of Xiamen University, Xiamen, China.,School of Medicine, Institute of Pediatrics, Xiamen University, Xiamen, China
| | - Yitian Li
- Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, School of Medicine, Eye Institute of Xiamen University, Xiamen University, Xiamen, China.,Department of Clinical Pharmacy, The Third Hospital of Mianyang/Sichuan Mental Health Center, Mianyang, China
| | - Sennan Xu
- Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, School of Medicine, Eye Institute of Xiamen University, Xiamen University, Xiamen, China
| | - Pan Zhou
- Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, School of Medicine, Eye Institute of Xiamen University, Xiamen University, Xiamen, China.,Department of Pathology, Qilu Hospital, Shandong University, Jinan, China
| | - Longhe Yang
- Technical Innovation Center for Utilization of Marine Biological Resources, Third Institute of Oceanography, Ministry of Natural Resources, Xiamen, China
| | - Yaping Xu
- Key Laboratory of Functional and Clinical Translational Medicine, Xiamen Medical College, Fujian Province University, Xiamen, China
| | - Yan Qiu
- Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, School of Medicine, Eye Institute of Xiamen University, Xiamen University, Xiamen, China.,Department of Clinical Pharmacy, The Third Hospital of Mianyang/Sichuan Mental Health Center, Mianyang, China
| | - Yungang Yang
- Department of Pediatrics, The First Affiliated Hospital of Xiamen University, Xiamen, China.,School of Medicine, Institute of Pediatrics, Xiamen University, Xiamen, China
| | - Yuhang Li
- CAS Key Laboratory of Design and Assembly of Functional Nanostructures and Fujian Provincial Key Laboratory of Nanomaterials, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fujian, China.,Xiamen Institute of Rare-earth Materials, Haixi Institutes, Chinese Academy of Sciences, Fujian, China
| |
Collapse
|
4
|
Rahman SMK, Uyama T, Hussain Z, Ueda N. Roles of Endocannabinoids and Endocannabinoid-like Molecules in Energy Homeostasis and Metabolic Regulation: A Nutritional Perspective. Annu Rev Nutr 2021; 41:177-202. [PMID: 34115519 DOI: 10.1146/annurev-nutr-043020-090216] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The endocannabinoid system is involved in signal transduction in mammals. It comprises principally G protein-coupled cannabinoid receptors and their endogenous agonists, called endocannabinoids, as well as the enzymes and transporters responsible for the metabolism of endocannabinoids. Two arachidonic acid-containing lipid molecules, arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol, function as endocannabinoids. N-acylethanolamines and monoacylglycerols, in which the arachidonic acid chain is replaced with a saturated or monounsaturated fatty acid, are not directly involved in the endocannabinoid system but exhibit agonistic activities for other receptors. These endocannabinoid-like molecules include palmitoylethanolamide, oleoylethanolamide (OEA), and 2-oleoylglycerol. Endocannabinoids stimulate feeding behavior and the anabolism of lipids and glucose, while OEA suppresses appetite. Both central and peripheral systems are included in these nutritional and metabolic contexts. Therefore, they have potential in the treatment and prevention of obesity. We outline the structure, metabolism, and biological activities of endocannabinoids and related molecules, and focus on their involvement in energy homeostasis and metabolic regulation. Expected final online publication date for the Annual Review of Nutrition, Volume 41 is September 2021. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.
Collapse
Affiliation(s)
- S M Khaledur Rahman
- Department of Biochemistry, Kagawa University School of Medicine, Miki, Kagawa 761-0793, Japan; , , .,Department of Genetic Engineering and Biotechnology, Jashore University of Science and Technology, Jashore-7408, Bangladesh
| | - Toru Uyama
- Department of Biochemistry, Kagawa University School of Medicine, Miki, Kagawa 761-0793, Japan; , ,
| | - Zahir Hussain
- Department of Biochemistry, Kagawa University School of Medicine, Miki, Kagawa 761-0793, Japan; , , .,Department of Pharmaceutical Sciences, School of Pharmacy, Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA;
| | - Natsuo Ueda
- Department of Biochemistry, Kagawa University School of Medicine, Miki, Kagawa 761-0793, Japan; , ,
| |
Collapse
|
5
|
Malamas MS, Pavlopoulos S, Alapafuja SO, Farah SI, Zvonok A, Mohammad KA, West J, Perry NT, Pelekoudas DN, Rajarshi G, Shields C, Chandrashekhar H, Wood J, Makriyannis A. Design and Structure-Activity Relationships of Isothiocyanates as Potent and Selective N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibitors. J Med Chem 2021; 64:5956-5972. [PMID: 33900772 DOI: 10.1021/acs.jmedchem.1c00076] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
N-Acylethanolamines are signaling lipid molecules implicated in pathophysiological conditions associated with inflammation and pain. N-Acylethanolamine acid amidase (NAAA) favorably hydrolyzes lipid palmitoylethanolamide, which plays a key role in the regulation of inflammatory and pain processes. The synthesis and structure-activity relationship studies encompassing the isothiocyanate pharmacophore have produced potent low nanomolar inhibitors for hNAAA, while exhibiting high selectivity (>100-fold) against other serine hydrolases and cysteine peptidases. We have followed a target-based structure-activity relationship approach, supported by computational methods and known cocrystals of hNAAA. We have identified systemically active inhibitors with good plasma stability (t1/2 > 2 h) and microsomal stability (t1/2 ∼ 15-30 min) as pharmacological tools to investigate the role of NAAA in inflammation, pain, and drug addiction.
Collapse
Affiliation(s)
| | - Spiro Pavlopoulos
- Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115, United States
| | - Shakiru O Alapafuja
- MAK Scientific LLC, 151 South Bedford Street, Burlington, Massachusetts 01803, United States
| | - Shrouq I Farah
- Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115, United States
| | - Alexander Zvonok
- Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115, United States
| | - Khadijah A Mohammad
- Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115, United States
| | - Jay West
- Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115, United States
| | - Nicholas Thomas Perry
- Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115, United States
| | - Dimitrios N Pelekoudas
- Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115, United States
| | - Girija Rajarshi
- Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115, United States
| | - Christina Shields
- Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115, United States
| | - Honrao Chandrashekhar
- Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115, United States
| | - Jodi Wood
- Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115, United States
| | - Alexandros Makriyannis
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115, United States
| |
Collapse
|
6
|
N-acylethanolamine acid amidase (NAAA) inhibition decreases the motivation for alcohol in Marchigian Sardinian alcohol-preferring rats. Psychopharmacology (Berl) 2021; 238:249-258. [PMID: 33037452 PMCID: PMC7796956 DOI: 10.1007/s00213-020-05678-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 10/05/2020] [Indexed: 10/23/2022]
Abstract
RATIONALE N-acylethanolamine acid amidase (NAAA) is an intracellular cysteine hydrolase that terminates the biological actions of oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), two endogenous lipid-derived agonists of the nuclear receptor, and peroxisome proliferator-activated receptor-α. OEA and PEA are important regulators of energy balance, pain, and inflammation, but recent evidence suggests that they might also contribute to the control of reward-related behaviors. OBJECTIVES AND METHODS In the present study, we investigated the effects of systemic and intracerebral NAAA inhibition in the two-bottle choice model of voluntary alcohol drinking and on operant alcohol self-administration. RESULTS Intraperitoneal injections of the systemically active NAAA inhibitor ARN19702 (3 and 10 mg/kg) lowered voluntary alcohol intake in a dose-dependent manner, achieving ≈ 47% reduction at the 10 mg/kg dose (p < 0.001). Water, food, or saccharin consumption was not affected by the inhibitor. Similarly, ARN19702 dose-dependently attenuated alcohol self-administration under both fixed ratio 1 (FR-1) and progressive ratio schedules of reinforcement. Furthermore, microinjection of ARN19702 (1, 3 and 10 μg/μl) or of two chemically different NAAA inhibitors, ARN077 and ARN726 (both at 3 and 10 μg/μl), into the midbrain ventral tegmental area produced dose-dependent decreases in alcohol self-administration under FR-1 schedule. Microinjection of ARN19702 into the nucleus accumbens had no such effect. CONCLUSION Collectively, the results point to NAAA as a possible molecular target for the treatment of alcohol use disorder.
Collapse
|
7
|
Chen T, Zhu G, Meng X, Zhang X. Recent developments of small molecules with anti-inflammatory activities for the treatment of acute lung injury. Eur J Med Chem 2020; 207:112660. [DOI: 10.1016/j.ejmech.2020.112660] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Revised: 07/05/2020] [Accepted: 07/10/2020] [Indexed: 12/22/2022]
|
8
|
Casili G, Lanza M, Campolo M, Siracusa R, Paterniti I, Ardizzone A, Scuderi SA, Cuzzocrea S, Esposito E. Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation. Int J Mol Sci 2020; 21:ijms21207486. [PMID: 33050589 PMCID: PMC7589809 DOI: 10.3390/ijms21207486] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Revised: 10/09/2020] [Accepted: 10/09/2020] [Indexed: 12/11/2022] Open
Abstract
Inflammation is a key element in the pathobiology of neurodegenerative diseases and sees the involvement of different neuronal and non-neuronal cells as players able to respond to inflammatory signals of immune origin. Palmitoylethanolamide (PEA) is an endogenous potent anti-inflammatory agent, in which activity is regulated by N-acylethanolamine acid amidase (NAAA), that hydrolyzes saturated or monounsaturated fatty acid ethanolamides, such as PEA. In this research, an in vitro study was performed on different neuronal (SH-SY5Y) and non-neuronal cell lines (C6, BV-2, and Mo3.13) subjected to NAAA enzyme silencing and treated with PEA ultra-micronized (PEA-um) (1, 3, and 10 μM) to increase the amount of endogenous PEA available for counteract neuroinflammation provoked by stimulation with lipopolysaccharide (LPS) (1 μg/mL) and interferon gamma (INF-γ )(100 U/mL). Cell viability was performed by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) staining, suggesting a protective effect of PEA-um (3 and 10 μM) on all cell lines studied. Western Blot analysis for inflammatory markers (Inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2)) was carried out in control and NAAA-silenced cells, highlighting how the concomitant treatment of the neuronal and non-neuronal cells with PEA-um after NAAA genic downregulation is satisfactory to counteract neuroinflammation. These in vitro findings support the protective role of endogenous PEA availability in the neuronal field, bringing interesting information for a translational point of view.
Collapse
Affiliation(s)
- Giovanna Casili
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy; (G.C.); (M.L.); (M.C.); (R.S.); (I.P.); (A.A.); (S.A.S.); (E.E.)
| | - Marika Lanza
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy; (G.C.); (M.L.); (M.C.); (R.S.); (I.P.); (A.A.); (S.A.S.); (E.E.)
| | - Michela Campolo
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy; (G.C.); (M.L.); (M.C.); (R.S.); (I.P.); (A.A.); (S.A.S.); (E.E.)
| | - Rosalba Siracusa
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy; (G.C.); (M.L.); (M.C.); (R.S.); (I.P.); (A.A.); (S.A.S.); (E.E.)
| | - Irene Paterniti
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy; (G.C.); (M.L.); (M.C.); (R.S.); (I.P.); (A.A.); (S.A.S.); (E.E.)
| | - Alessio Ardizzone
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy; (G.C.); (M.L.); (M.C.); (R.S.); (I.P.); (A.A.); (S.A.S.); (E.E.)
| | - Sarah Adriana Scuderi
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy; (G.C.); (M.L.); (M.C.); (R.S.); (I.P.); (A.A.); (S.A.S.); (E.E.)
| | - Salvatore Cuzzocrea
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy; (G.C.); (M.L.); (M.C.); (R.S.); (I.P.); (A.A.); (S.A.S.); (E.E.)
- Department of Pharmacological and Physiological Science, Saint Louis University, Saint Louis, MO 63103, USA
- Correspondence: ; Tel.: +39-090-6765208
| | - Emanuela Esposito
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy; (G.C.); (M.L.); (M.C.); (R.S.); (I.P.); (A.A.); (S.A.S.); (E.E.)
| |
Collapse
|
9
|
Yang L, Ji C, Li Y, Hu F, Zhang F, Zhang H, Li L, Ren J, Wang Z, Qiu Y. Natural Potent NAAA Inhibitor Atractylodin Counteracts LPS-Induced Microglial Activation. Front Pharmacol 2020; 11:577319. [PMID: 33117168 PMCID: PMC7565389 DOI: 10.3389/fphar.2020.577319] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Accepted: 09/08/2020] [Indexed: 12/19/2022] Open
Abstract
N-acylethanolamine-hydrolyzing acid amidase (NAAA) is a lysosomal enzyme that inhibits the degradation of palmitoylethanolamide (PEA), an endogenous lipid that induces analgesic, anti-inflammation, and anti-multiple sclerosis through PPARα activation. Only a few potent NAAA inhibitors have been reported to date, which is mainly due to the restricted substrate-binding site of NAAA. Here, we established a high-throughput fluorescence-based assay for NAAA inhibitor screening. Several new classes of NAAA inhibitors were discovered from a small library of natural products. One of these is atractylodin, a polyethylene alkyne compound from the root of Atractylodes lancea (Thunb) DC., which significantly inhibits NAAA activity and has an IC50 of 2.81 µM. Kinetic analyses and dialysis assays suggested that atractylodin engages in competitive inhibition via reversible reaction to the enzyme. Docking assays revealed that atractylodin occupies the catalytic cavity of NAAA, where the atractylodin furan head group has a hydrophobic-related interaction with the backbone of the Trp181 and Leu152 residues of human NAAA. Further investigation indicated that atractylodin significantly increases PEA and OEA levels and dose-dependently inhibits LPS-induced nitrate, TNF-α, IL-1β, and IL-6 pro-inflammatory cytokine release in BV-2 microglia. Our results show that atractylodin elevates cellular PEA levels and inhibits microglial activation by inhibiting NAAA activity, which in turn could contribute to NAAA functional research.
Collapse
Affiliation(s)
- Longhe Yang
- Technical Innovation Center for Utilization of Marine Biological Resources, Third Institute of Oceanography, Ministry of Natural Resources, Xiamen, China
| | - Chunyan Ji
- Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, School of Medicine, Xiamen University, Xiamen, China
| | - Yitian Li
- Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, School of Medicine, Xiamen University, Xiamen, China
| | - Fan Hu
- Technical Innovation Center for Utilization of Marine Biological Resources, Third Institute of Oceanography, Ministry of Natural Resources, Xiamen, China
| | - Fang Zhang
- Technical Innovation Center for Utilization of Marine Biological Resources, Third Institute of Oceanography, Ministry of Natural Resources, Xiamen, China
| | - Haiping Zhang
- Center for High Performance Computing, Joint Engineering Research Center for Health Big Data Intelligent Analysis Technology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
| | - Long Li
- Institute of Drug Discovery Technology, Ningbo University, Ningbo, China
| | - Jie Ren
- Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, School of Medicine, Xiamen University, Xiamen, China
| | - Zhaokai Wang
- Technical Innovation Center for Utilization of Marine Biological Resources, Third Institute of Oceanography, Ministry of Natural Resources, Xiamen, China
| | - Yan Qiu
- Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, School of Medicine, Xiamen University, Xiamen, China
| |
Collapse
|
10
|
Assessment of candidate biomarkers to detect resistance to Mycobacterium bovis in Holstein-Friesian cattle. Res Vet Sci 2020; 132:416-425. [PMID: 32768870 DOI: 10.1016/j.rvsc.2020.07.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Revised: 05/30/2020] [Accepted: 07/22/2020] [Indexed: 11/22/2022]
Abstract
Bovine tuberculosis (bTB) caused by Mycobacterium bovis has a significant economic impact worldwide each year. Control of bTB is based on skin testing and removal of reactors. However, additional strategies are required to control this disorder. Natural disease resistance has been defined as the inherent capacity of an individual to resist disease when exposed to pathogens without previous exposure or immunization. However, little is known about natural disease resistance against Mycobacterium bovis in cattle. In this study, we aimed to identify candidate biomarkers to detect host resistance to M. bovis. We used a microbicidal assay to identify the resistance phenotype. A genomic microarray analysis was carried out on RNA from 2 resistant (R) and 2 susceptible (S) cows. Our results evidenced 69 differentially expressed genes. A subset of six genes that showed differential up (IL1RN), and down-regulation (VNN, GATM, ARHGEF11, NAAA and HSPA2) were selected for further analysis. To further validate the candidate biomarkers, we identified the R phenotype in 31 cattle (9 R and 22 S). Macrophage mRNA was isolated from this group of cattle. Expression of candidate biomarkers was evaluated by qPCR 2-ΔCt and ROC curves to determine their diagnostic potential. Candidates IL1RN and ARHGEF11 discriminates between R and S cattle. Furthermore, combination of candidates ARHGEF11: VNN: HSPA2 discriminate between R from S with AUC 0.7993 and agreement index of 0.853 (p ≤ 0.01). Our data suggest that candidate biomarkers may support the preliminary screening to identify natural resistance in herds against Mycobacterium bovis in Holstein-Friesian cattle.
Collapse
|
11
|
Ren T, Ma A, Zhuo R, Zhang H, Peng L, Jin X, Yao E, Yang L. Oleoylethanolamide Increases Glycogen Synthesis and Inhibits Hepatic Gluconeogenesis via the LKB1/AMPK Pathway in Type 2 Diabetic Model. J Pharmacol Exp Ther 2020; 373:81-91. [PMID: 32024803 DOI: 10.1124/jpet.119.262675] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Accepted: 01/07/2020] [Indexed: 12/12/2022] Open
Abstract
Oleoylethanolamide (OEA) is an endogenous peroxisome proliferator-activated receptor α (PPARα) agonist that acts on the peripheral control of energy metabolism. However, its therapeutic potential and related mechanisms in hepatic glucose metabolism under type 2 diabetes mellitus (T2DM) are not clear. Here, OEA treatment markedly improved glucose homeostasis in a PPARα-independent manner. OEA efficiently promoted glycogen synthesis and suppressed gluconeogenesis in mouse primary hepatocytes and liver tissue. OEA enhanced hepatic glycogen synthesis and inhibited gluconeogenesis via liver kinase B1 (LKB1)/5' AMP-activated protein kinase (AMPK) signaling pathways. PPARα was not involved in the roles of OEA in the LKB1/AMPK pathways. We found that OEA exerts its antidiabetic effect by increasing glycogenesis and decreasing gluconeogenesis via the LKB1/AMPK pathway. The ability of OEA to control hepatic LKB1/AMPK pathways may serve as a novel therapeutic approach for the treatment of T2DM. SIGNIFICANCE STATEMENT: Oleoylethanolamide (OEA) exerted a potent antihyperglycemic effect in a peroxisome proliferator-activated receptor α-independent manner. OEA played an antihyperglycemic role primarily via regulation of hepatic glycogen synthesis and gluconeogenesis. The main molecular mechanism of OEA in regulating liver glycometabolism is activating the liver kinase B1/5' AMP-activated protein kinase signaling pathways.
Collapse
Affiliation(s)
- Tong Ren
- Xiamen Key Laboratory of Chiral Drugs, School of Medicine, Xiamen University, Xiamen, China (T.R., A.M., R.Z., H.Z., L.P., X.J., L.Y.) and Department of Cardiology, Fujian Medical University Union Hospital, Fujian Institute of Coronary Artery Disease, Fujian Heart Medical Center, Fuzhou, China (E.Y.)
| | - Ang Ma
- Xiamen Key Laboratory of Chiral Drugs, School of Medicine, Xiamen University, Xiamen, China (T.R., A.M., R.Z., H.Z., L.P., X.J., L.Y.) and Department of Cardiology, Fujian Medical University Union Hospital, Fujian Institute of Coronary Artery Disease, Fujian Heart Medical Center, Fuzhou, China (E.Y.)
| | - Rengong Zhuo
- Xiamen Key Laboratory of Chiral Drugs, School of Medicine, Xiamen University, Xiamen, China (T.R., A.M., R.Z., H.Z., L.P., X.J., L.Y.) and Department of Cardiology, Fujian Medical University Union Hospital, Fujian Institute of Coronary Artery Disease, Fujian Heart Medical Center, Fuzhou, China (E.Y.)
| | - Huaying Zhang
- Xiamen Key Laboratory of Chiral Drugs, School of Medicine, Xiamen University, Xiamen, China (T.R., A.M., R.Z., H.Z., L.P., X.J., L.Y.) and Department of Cardiology, Fujian Medical University Union Hospital, Fujian Institute of Coronary Artery Disease, Fujian Heart Medical Center, Fuzhou, China (E.Y.)
| | - Lu Peng
- Xiamen Key Laboratory of Chiral Drugs, School of Medicine, Xiamen University, Xiamen, China (T.R., A.M., R.Z., H.Z., L.P., X.J., L.Y.) and Department of Cardiology, Fujian Medical University Union Hospital, Fujian Institute of Coronary Artery Disease, Fujian Heart Medical Center, Fuzhou, China (E.Y.)
| | - Xin Jin
- Xiamen Key Laboratory of Chiral Drugs, School of Medicine, Xiamen University, Xiamen, China (T.R., A.M., R.Z., H.Z., L.P., X.J., L.Y.) and Department of Cardiology, Fujian Medical University Union Hospital, Fujian Institute of Coronary Artery Disease, Fujian Heart Medical Center, Fuzhou, China (E.Y.)
| | - Enhui Yao
- Xiamen Key Laboratory of Chiral Drugs, School of Medicine, Xiamen University, Xiamen, China (T.R., A.M., R.Z., H.Z., L.P., X.J., L.Y.) and Department of Cardiology, Fujian Medical University Union Hospital, Fujian Institute of Coronary Artery Disease, Fujian Heart Medical Center, Fuzhou, China (E.Y.)
| | - Lichao Yang
- Xiamen Key Laboratory of Chiral Drugs, School of Medicine, Xiamen University, Xiamen, China (T.R., A.M., R.Z., H.Z., L.P., X.J., L.Y.) and Department of Cardiology, Fujian Medical University Union Hospital, Fujian Institute of Coronary Artery Disease, Fujian Heart Medical Center, Fuzhou, China (E.Y.)
| |
Collapse
|
12
|
Malamas MS, Farah SI, Lamani M, Pelekoudas DN, Perry NT, Rajarshi G, Miyabe CY, Chandrashekhar H, West J, Pavlopoulos S, Makriyannis A. Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors. Bioorg Med Chem 2019; 28:115195. [PMID: 31761726 DOI: 10.1016/j.bmc.2019.115195] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Revised: 10/29/2019] [Accepted: 10/30/2019] [Indexed: 10/25/2022]
Abstract
N-acylethanolamine acid amidase (NAAA) inhibition represents an exciting novel approach to treat inflammation and pain. NAAA is a cysteine amidase which preferentially hydrolyzes the endogenous biolipids palmitoylethanolamide (PEA) and oleoylethanolamide (OEA). PEA is an endogenous agonist of the nuclear peroxisome proliferator-activated receptor-α (PPAR-α), which is a key regulator of inflammation and pain. Thus, blocking the degradation of PEA with NAAA inhibitors results in augmentation of the PEA/PPAR-α signaling pathway and regulation of inflammatory and pain processes. We have prepared a new series of NAAA inhibitors exploring the azetidine-nitrile (cyanamide) pharmacophore that led to the discovery of highly potent and selective compounds. Key analogs demonstrated single-digit nanomolar potency for hNAAA and showed >100-fold selectivity against serine hydrolases FAAH, MGL and ABHD6, and cysteine protease cathepsin K. Additionally, we have identified potent and selective dual NAAA-FAAH inhibitors to investigate a potential synergism between two distinct anti-inflammatory molecular pathways, the PEA/PPAR-α anti-inflammatory signaling pathway,1-4 and the cannabinoid receptors CB1 and CB2 pathways which are known for their antiinflammatory and antinociceptive properties.5-8 Our ligand design strategy followed a traditional structure-activity relationship (SAR) approach and was supported by molecular modeling studies of reported X-ray structures of hNAAA. Several inhibitors were evaluated in stability assays and demonstrated very good plasma stability (t1/2 > 2 h; human and rodents). The disclosed cyanamides represent promising new pharmacological tools to investigate the potential role of NAAA inhibitors and dual NAAA-FAAH inhibitors as therapeutic agents for the treatment of inflammation and pain.
Collapse
Affiliation(s)
- Michael S Malamas
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States.
| | - Shrouq I Farah
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States
| | - Manjunath Lamani
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States
| | - Dimitrios N Pelekoudas
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States
| | - Nicholas Thomas Perry
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States
| | - Girija Rajarshi
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States
| | - Christina Yume Miyabe
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States
| | - Honrao Chandrashekhar
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States
| | - Jay West
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States
| | - Spiro Pavlopoulos
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States
| | - Alexandros Makriyannis
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States
| |
Collapse
|
13
|
N-Palmitoylethanolamide-Oxazoline Protects against Middle Cerebral Artery Occlusion Injury in Diabetic Rats by Regulating the SIRT1 Pathway. Int J Mol Sci 2019; 20:ijms20194845. [PMID: 31569558 PMCID: PMC6801841 DOI: 10.3390/ijms20194845] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2019] [Revised: 09/23/2019] [Accepted: 09/25/2019] [Indexed: 12/19/2022] Open
Abstract
Diabetes causes various macrovascular and microvascular alterations, often culminating in major clinical complications (first of all, stroke) that lack an effective therapeutic intervention. N-palmitoylethanolamide-oxazoline (PEA-OXA) possesses anti-inflammatory and potent neuroprotective effects. Although recent studies have explained the neuroprotective properties of PEA-OXA, nothing is known about its effects in treating cerebral ischemia. Methods: Focal cerebral ischemia was induced by transient middle cerebral artery occlusion (MCAo) in the right hemisphere. Middle cerebral artery (MCA) occlusion was provided by introducing a 4–0 nylon monofilament (Ethilon; Johnson & Johnson, Somerville, NJ, USA) precoated with silicone via the external carotid artery into the internal carotid artery to occlude the MCA. Results: A neurological severity score and infarct volumes were carried out to assess the neuroprotective effects of PEA-OXA. Moreover, we observed PEA-OXA-mediated improvements in tissue histology shown by a reduction in lesion size and an improvement in apoptosis level (assessed by caspases, Bax, and Bcl-2 modulation and a TUNEL assay), which further supported the efficacy of PEA-OXA therapy. We also found that PEA-OXA treatment was able to reduce mast cell degranulation and reduce the MCAo-induced expression of NF-κB pathways, cytokines, and neurotrophic factors. Conclusions: based on these findings, we propose that PEA-OXA could be useful in decreasing the risk of impairment or improving function in ischemia/reperfusion brain injury-related disorders.
Collapse
|
14
|
N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritis. Pharmacol Res 2019; 145:104264. [PMID: 31063807 DOI: 10.1016/j.phrs.2019.104264] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Revised: 04/22/2019] [Accepted: 05/03/2019] [Indexed: 12/15/2022]
Abstract
Osteoarthritis (OA), characterized by cartilage damage, synovitis inflammation and chronic pain, is a common degenerative joint disease that may lead to physical disability. In the present study, we first explored the association between N-Acylethanolamine acid amidase (NAAA) and OA progression, and then examined the capability of the NAAA inhibitor F215 to attenuate osteoarthritis. Increased NAAA expressions and decreased PEA levels in synovial membrane and lumbar spinal cord were observed in MIA induced osteoarthritic rats. F215 (i.a., and i.p.) significantly protected against cartilage damage and synovial inflammation by directly increasing PEA levels in joints, or normalization of PEA levels and resolution of inflammation in spinal cord. Moreover, F215 also markedly alleviated osteoarthritic pain in rats, and the therapeutic effects of F215 were blocked by the PPAR-α antagonist MK886. The results revealed that NAAA may has been implicated in OA progression, and treatment with NAAA inhibitor F215 alleviated OA development by preventing cartilage damage, reducing inflammation, and alleviating pain. Our study suggested that NAAA inhibitor might be a novel therapeutic agent for OA treatment.
Collapse
|
15
|
Rivera P, Silva-Peña D, Blanco E, Vargas A, Arrabal S, Serrano A, Pavón FJ, Bindila L, Lutz B, Rodríguez de Fonseca F, Suárez J. Oleoylethanolamide restores alcohol-induced inhibition of neuronal proliferation and microglial activity in striatum. Neuropharmacology 2019; 146:184-197. [DOI: 10.1016/j.neuropharm.2018.11.037] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 11/08/2018] [Accepted: 11/25/2018] [Indexed: 01/19/2023]
|
16
|
Zhou P, Xiang L, Zhao D, Ren J, Qiu Y, Li Y. Synthesis, biological evaluation, and structure activity relationship (SAR) study of pyrrolidine amide derivatives as N-acylethanolamine acid amidase (NAAA) inhibitors. MEDCHEMCOMM 2018; 10:252-262. [PMID: 30931090 DOI: 10.1039/c8md00432c] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Accepted: 12/14/2018] [Indexed: 01/15/2023]
Abstract
N-Acylethanolamine acid amidase (NAAA) is one of the key enzymes involved in the degradation of fatty acid ethanolamides (FAEs), especially for palmitoylethanolamide (PEA). Pharmacological blockage of NAAA restores PEA levels, providing therapeutic benefits in the management of inflammation and pain. In the current work, we showed the structure-activity relationship (SAR) studies for pyrrolidine amide derivatives as NAAA inhibitors. A series of aromatic replacements or substituents for the terminal phenyl group of pyrrolidine amides were examined. SAR data showed that small lipophilic 3-phenyl substituents were preferable for optimal potency. The conformationally flexible linkers increased the inhibitory potency of pyrrolidine amide derivatives but reduced their selectivity toward fatty acid amide hydrolase (FAAH). The conformationally restricted linkers did not enhance the inhibitor potency toward NAAA but improved the selectivity over FAAH. Several low micromolar potent NAAA inhibitors were developed, including 4g bearing a rigid 4-phenylcinnamoyl group. Dialysis and kinetic analysis suggested that 4g inhibited NAAA via a competitive and reversible mechanism. Furthermore, 4g showed high anti-inflammatory activities in lipopolysaccharide (LPS) induced acute lung injury (ALI) model, and this effect was blocked by pre-treatment with the PPAR-α antagonist MK886. We anticipate that 4g (E93) will enable a new agent to treat inflammation and related diseases.
Collapse
Affiliation(s)
- Pan Zhou
- Eye Institute of Xiamen University , Xiamen , Fujian 361102 , China.,Medical College , Xiamen University , Xiamen , Fujian 361102 , China
| | - Lei Xiang
- Medical College , Xiamen University , Xiamen , Fujian 361102 , China
| | - Dongsheng Zhao
- Department of Pharmacy , Quanzhou Medical College , China . Tel: Quanzhou 362100
| | - Jie Ren
- Eye Institute of Xiamen University , Xiamen , Fujian 361102 , China.,Medical College , Xiamen University , Xiamen , Fujian 361102 , China
| | - Yan Qiu
- Eye Institute of Xiamen University , Xiamen , Fujian 361102 , China.,Medical College , Xiamen University , Xiamen , Fujian 361102 , China
| | - Yuhang Li
- Xiamen Institute of Rare-earth Materials , Haixi Institutes , Chinese Academy of Sciences , Fujian 361005 , China.,CAS Key Laboratory of Design and Assembly of Functional Nanostructures , and Fujian Provincial Key Laboratory of Nanomaterials , Fujian Institute of Research on the Structure of Matter , Chinese Academy of Sciences , China .
| |
Collapse
|
17
|
Chiurchiù V, Leuti A, Smoum R, Mechoulam R, Maccarrone M. Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes. FASEB J 2018; 32:5716-5723. [PMID: 29879374 DOI: 10.1096/fj.201800107r] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Autacoid local injury antagonist amides (ALIAmides) are a family of endogenous bioactive acyl ethanolamides that include the renowned palmitoyl ethanolamide (PEA), oleoyl ethanolamide (OEA), and stearoyl ethanolamide (SEA), and that are involved in several biologic processes such as nociception, lipid metabolism, and inflammation. The role of ALIAmides in the control of inflammatory processes has recently gained much attention and prompted the use of these molecules or their analogs, and the pharmacologic manipulation of their endogenous levels, as plausible therapeutic strategies in the treatment of several chronic inflammatory conditions. Since chronic inflammation is mainly driven by cells of adaptive immunity, particularly T lymphocytes, we aimed at investigating whether such bioactive lipids could directly modulate T-cell responses. We found that OEA, PEA, and eicosatrienoyl ethanolamide (ETEA) could directly inhibit both T-cell responses by reducing their production of TNF-α and IFN-γ from CD8 T cells and TNF-α, IFN-γ and IL-17 from CD4 T cells. Furthermore, neither SEA nor docosatrienoyl ethanolamide (DTEA) could affect cytokine production from both T cell subsets. Interestingly, unlike OEA and ETEA, PEA was also able to enhance de novo generation of forkhead box P3 (FoxP3)-expressing regulatory T cells from CD4-naive T cells. Our findings show for the first time that specific ALIAmides can directly affect different T-cell subsets, and provide proof of their anti-inflammatory role in chronic inflammation, ultimately suggesting that these bioactive lipids could offer novel tools for the management of T-cell dependent chronic inflammatory diseases.-Chiurchiù, V., Leuti, A., Smoum, R., Mechoulam, R., Maccarrone, M. Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes.
Collapse
Affiliation(s)
- Valerio Chiurchiù
- Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.,Neurochemistry of Lipids, European Center for Brain Research (CERC), Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Santa Lucia Foundation, Rome, Italy; and
| | - Alessandro Leuti
- Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.,Neurochemistry of Lipids, European Center for Brain Research (CERC), Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Santa Lucia Foundation, Rome, Italy; and
| | - Reem Smoum
- Institute for Cannabinoid Research, Hebrew University Medical Faculty, Jerusalem, Israel
| | - Raphael Mechoulam
- Institute for Cannabinoid Research, Hebrew University Medical Faculty, Jerusalem, Israel
| | - Mauro Maccarrone
- Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy.,Neurochemistry of Lipids, European Center for Brain Research (CERC), Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Santa Lucia Foundation, Rome, Italy; and
| |
Collapse
|
18
|
Inflammation-restricted anti-inflammatory activities of a N -acylethanolamine acid amidase (NAAA) inhibitor F215. Pharmacol Res 2018; 132:7-14. [DOI: 10.1016/j.phrs.2018.03.011] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Revised: 03/14/2018] [Accepted: 03/15/2018] [Indexed: 11/21/2022]
|
19
|
Bonsale R, Seyed Sharifi R, Dirandeh E, Hedayat N, Mojtahedin A, Ghorbanalinia M, Abolghasemi A. Endocannabinoids as endometrial inflammatory markers in lactating Holstein cows. Reprod Domest Anim 2018. [DOI: 10.1111/rda.13169] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- R Bonsale
- Department of Animal Sciences; College of Agricultural Sciences and Natural Resources; University of Mohaghegh Ardabili; Ardabil Iran
| | - R Seyed Sharifi
- Department of Animal Sciences; College of Agricultural Sciences and Natural Resources; University of Mohaghegh Ardabili; Ardabil Iran
| | - E Dirandeh
- Department of Animal Sciences; Sari Agricultural Sciences and Natural Resources University; Sari Iran
| | - N Hedayat
- Department of Animal Sciences; College of Agricultural Sciences and Natural Resources; University of Mohaghegh Ardabili; Ardabil Iran
| | - A Mojtahedin
- Department of Animal Sciences; College of Agricultural Sciences and Natural Resources; University of Mohaghegh Ardabili; Ardabil Iran
| | - M Ghorbanalinia
- Department of Animal Sciences; Sari Agricultural Sciences and Natural Resources University; Sari Iran
| | - A Abolghasemi
- Section of Physiology; Department of Biomedical Sciences; University of Cagliari; Cagliari Sardegna Italy
| |
Collapse
|
20
|
Khatri D, Laroche G, Grant ML, Jones VM, Vetreno RP, Crews FT, Mukhopadhyay S. Acute Ethanol Inhibition of Adult Hippocampal Neurogenesis Involves CB1 Cannabinoid Receptor Signaling. Alcohol Clin Exp Res 2018; 42:718-726. [PMID: 29417597 DOI: 10.1111/acer.13608] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2017] [Accepted: 01/30/2018] [Indexed: 12/26/2022]
Abstract
BACKGROUND Chronic ethanol (EtOH) exposure has been found to inhibit adult hippocampal neurogenesis in multiple models of alcohol addiction. However, acute EtOH inhibition of adult neurogenesis is not well studied. Although many abused drugs have been found to inhibit adult neurogenesis, few have studied cannabinoids or cannabinoids with EtOH, although human use of both together is becoming more common. We used an acute binge alcohol drinking model in combination with select cannabinoid receptor agonists and antagonists to investigate the actions of each alone and together on hippocampal neurogenesis. METHODS Adult male Wistar rats were treated with an acute binge dose of EtOH (5 g/kg, i.g.), cannabinoid 1 receptor (CB1R) or cannabinoid 2 receptor (CB2R) agonists, as well as selective cannabinoid (CB) antagonists, alone or combined. Hippocampal doublecortin (DCX), Ki67, and activated cleaved caspase-3 (CC3) immunohistochemistry were used to assess neurogenesis, neuroprogenitor proliferation, and cell death, respectively. RESULTS We found that treatment with EtOH or the CB1R agonist, arachidonoyl-2'-chloroethylamide (ACEA), and the combination significantly reduced DCX-positive neurons (DCX + IR) in dentate gyrus (DG) and increased CC3. Further, using an inhibitor of endocannabinoid metabolism, for example, JZL195, we also found reduced DCX + IR neurogenesis. Treatment with 2 different CB1R antagonists (AM251 or SR141716) reversed both CB1R agonist and EtOH inhibition of adult neurogenesis. CB2R agonist HU-308 treatment did not produce any significant change in DCX + IR. Interestingly, neither EtOH nor CB1R agonist produced any alteration in cell proliferation in DG as measured by Ki67 + cell population, but CC3-positive cell numbers increased following EtOH or ACEA treatment suggesting an increase in cell death. CONCLUSIONS Together, these findings suggest that acute CB1R cannabinoid receptor activation and binge EtOH treatment reduce neurogenesis through mechanisms involving CB1R.
Collapse
Affiliation(s)
- Dal Khatri
- Neuroscience Research Program, Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, North Carolina
| | - Genevieve Laroche
- Neuroscience Research Program, Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, North Carolina
| | - Marion L Grant
- Department of Biology, North Carolina Central University, Durham, North Carolina
| | - Victoria M Jones
- Department of Chemistry & Biochemistry, North Carolina Central University, Durham, North Carolina
| | - Ryan P Vetreno
- Bowles Alcohol Research Center, UNC-Chapel Hill School of Medicine, Chapel Hill, North Carolina
| | - Fulton T Crews
- Bowles Alcohol Research Center, UNC-Chapel Hill School of Medicine, Chapel Hill, North Carolina.,Department of Pharmacology, UNC-Chapel Hill School of Medicine, Chapel Hill, North Carolina
| | - Somnath Mukhopadhyay
- Neuroscience Research Program, Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, North Carolina.,Department of Chemistry & Biochemistry, North Carolina Central University, Durham, North Carolina.,Department of Pharmacology, UNC-Chapel Hill School of Medicine, Chapel Hill, North Carolina
| |
Collapse
|
21
|
Sasso O, Summa M, Armirotti A, Pontis S, De Mei C, Piomelli D. The N-Acylethanolamine Acid Amidase Inhibitor ARN077 Suppresses Inflammation and Pruritus in a Mouse Model of Allergic Dermatitis. J Invest Dermatol 2018; 138:562-569. [DOI: 10.1016/j.jid.2017.07.853] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Revised: 07/13/2017] [Accepted: 07/21/2017] [Indexed: 01/12/2023]
|
22
|
Roviezzo F, Rossi A, Caiazzo E, Orlando P, Riemma MA, Iacono VM, Guarino A, Ialenti A, Cicala C, Peritore A, Capasso R, Di Marzo V, Izzo AA. Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse. Front Pharmacol 2017; 8:857. [PMID: 29311913 PMCID: PMC5732963 DOI: 10.3389/fphar.2017.00857] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Accepted: 11/08/2017] [Indexed: 02/06/2023] Open
Abstract
One important risk factor for the development of asthma is allergen sensitization. Recent increasing evidence suggests a prominent role of mast cells in asthma pathophysiology. Since Palmitoylethanolamide (PEA), an endogenous lipid mediator chemically related to - and co-released with- the endocannabinoid anandamide, behaves as a local autacoid down-regulator of mast cell activation and inflammation, we explored the possible contribution of PEA in allergic sensitization, by using ovalbumin (OVA) as sensitizing agent in the mouse. PEA levels were dramatically reduced in the bronchi of OVA-treated animals. This effect was coupled to a significant up-regulation of CB2 and GPR55 receptors, two of the proposed molecular PEA targets, in bronchi harvested from allergen-sensitized mice. PEA supplementation (10 mg/kg, 15 min before each allergen exposure) prevented OVA-induced bronchial hyperreactivity, but it did not affect IgE plasma increase. On the other hand, PEA abrogated allergen-induced cell recruitment as well as pulmonary inflammation. Evaluation of pulmonary sections evidenced a significant inhibitory action of PEA on pulmonary mast cell recruitment and degranulation, an effect coupled to a reduction of leukotriene C4 production. These findings demonstrate that allergen sensitization negatively affects PEA bronchial levels and suggest that its supplementation has the potential to prevent the development of asthma-like features.
Collapse
Affiliation(s)
- Fiorentina Roviezzo
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples, Italy
| | - Antonietta Rossi
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples, Italy
| | - Elisabetta Caiazzo
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples, Italy
| | - Pierangelo Orlando
- Institute of Protein Biochemistry, National Research Council, Naples, Italy.,Institute of Applied Sciences and Intelligent Systems, National Research Council, Naples, Italy.,Endocannabinoid Research Group, Naples, Italy
| | - Maria A Riemma
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples, Italy
| | - Valentina M Iacono
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples, Italy
| | - Andrea Guarino
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples, Italy
| | - Armando Ialenti
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples, Italy
| | - Carla Cicala
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples, Italy
| | - Alessio Peritore
- Endocannabinoid Research Group, Naples, Italy.,Institute of Biomolecular Chemistry, National Research Council, Naples, Italy
| | - Raffaele Capasso
- Endocannabinoid Research Group, Naples, Italy.,Department of Agricultural Sciences, University of Naples Federico II, Portici, Italy
| | - Vincenzo Di Marzo
- Endocannabinoid Research Group, Naples, Italy.,Institute of Biomolecular Chemistry, National Research Council, Naples, Italy
| | - Angelo A Izzo
- Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples, Italy.,Endocannabinoid Research Group, Naples, Italy
| |
Collapse
|
23
|
Li Y, Chen Q, Yang L, Li Y, Zhang Y, Qiu Y, Ren J, Lu C. Identification of highly potent N -acylethanolamine acid amidase (NAAA) inhibitors: Optimization of the terminal phenyl moiety of oxazolidone derivatives. Eur J Med Chem 2017; 139:214-221. [DOI: 10.1016/j.ejmech.2017.08.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Revised: 07/24/2017] [Accepted: 08/02/2017] [Indexed: 12/30/2022]
|
24
|
Petrosino S, Campolo M, Impellizzeri D, Paterniti I, Allarà M, Gugliandolo E, D'Amico R, Siracusa R, Cordaro M, Esposito E, Di Marzo V, Cuzzocrea S. 2-Pentadecyl-2-Oxazoline, the Oxazoline of Pea, Modulates Carrageenan-Induced Acute Inflammation. Front Pharmacol 2017; 8:308. [PMID: 28611664 PMCID: PMC5448350 DOI: 10.3389/fphar.2017.00308] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Accepted: 05/11/2017] [Indexed: 12/21/2022] Open
Abstract
N-acylethanolamines (NAEs) involve a family of lipid molecules existent in animal and plant, with N-palmitoylethanolamide (PEA) that arouses great attention owing to its anti-inflammatory, analgesic and neuroprotective activities. Because PEA is produced on demand and exerts pleiotropic effects, the modulation of specific amidases for NAEs (and in particular NAE-hydrolyzing acid amidase NAAA, which is more selective for PEA) could be a condition to preserve its levels. Here we investigate the effect of 2-Pentadecyl-2-oxazoline (PEA-OXA) the oxazoline of PEA, on human recombinant NAAA in vitro and in an established model of Carrageenan (CAR)-induced rat paw inflammation. PEA-OXA dose-dependently significantly inhibited recombinant NAAA and, orally administered to rats (10 mg/kg), limiting histological damage, thermal hyperalgesia and the increase of infiltrating inflammatory cells after CAR injection in the rat right hindpaw, compared to ultramicronized PEA given orally at the same dose (10 mg/kg). These effects were accompanied by elevation of paw PEA levels. Moreover, PEA-OXA markedly reduced neutrophil infiltration and pro-inflammatory cytokine release and prevented CAR-induced IκB-α degradation, nuclear translocation of NF-κB p65, the increase of inducible nitric oxide synthase, cyclooxygenase-2, intercellular adhesion molecule-1, and mast cell activation. Experiments in PPAR-α knockout mice showed that the anti-inflammatory effects of PEA-OXA were not dependent on the presence of PPAR-α receptors. In conclusion, NAAA modulators as PEA-OXA could help to maximize the tissue availability of PEA by increasing its levels and anti-inflammatory effects.
Collapse
Affiliation(s)
- Stefania Petrosino
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle RicerchePozzuoli, Italy.,Epitech Group SpASaccolongo, Italy
| | - Michela Campolo
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of MessinaMessina, Italy
| | - Daniela Impellizzeri
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of MessinaMessina, Italy
| | - Irene Paterniti
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of MessinaMessina, Italy
| | - Marco Allarà
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle RicerchePozzuoli, Italy.,Epitech Group SpASaccolongo, Italy
| | - Enrico Gugliandolo
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of MessinaMessina, Italy
| | - Ramona D'Amico
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of MessinaMessina, Italy
| | - Rosalba Siracusa
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of MessinaMessina, Italy
| | - Marika Cordaro
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of MessinaMessina, Italy
| | - Emanuela Esposito
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of MessinaMessina, Italy
| | - Vincenzo Di Marzo
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle RicerchePozzuoli, Italy
| | - Salvatore Cuzzocrea
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of MessinaMessina, Italy
| |
Collapse
|
25
|
Alhouayek M, Bottemanne P, Makriyannis A, Muccioli GG. N -acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N -acylethanolamine levels and macrophage activation. Biochim Biophys Acta Mol Cell Biol Lipids 2017; 1862:474-484. [DOI: 10.1016/j.bbalip.2017.01.001] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Revised: 11/20/2016] [Accepted: 01/04/2017] [Indexed: 11/16/2022]
|
26
|
Pacholewska A, Marti E, Leeb T, Jagannathan V, Gerber V. LPS-induced modules of co-expressed genes in equine peripheral blood mononuclear cells. BMC Genomics 2017; 18:34. [PMID: 28056766 PMCID: PMC5217269 DOI: 10.1186/s12864-016-3390-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Accepted: 12/07/2016] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Lipopolysaccharide (endotoxin, LPS) is a strong inducer of the innate immune response. It is widespread in our environment, e.g. in house dust and contributes to asthma. Compared to humans, horses are even more sensitive to LPS. However, data on LPS effects on the equine transcriptome are very limited. Using RNA-seq we analysed LPS-induced differences in the gene expression in equine peripheral blood mononuclear cells at the gene and gene-network level in two half-sib families and one group of unrelated horses. RESULTS 24 h-LPS challenge of equine immune cells resulted in substantial changes in the transcriptomic profile (1,265 differentially expressed genes) showing partial overlap with human data. One of the half-sib families showed a specific response different from the other two groups of horses. We also identified co-expressed gene modules that clearly differentiated 24 h-LPS- from non-stimulated samples. These modules consisted of 934 highly interconnected genes and included genes involved in the immune response (e.g. IL6, CCL22, CXCL6, CXCL2), however, none of the top ten hub genes of the modules have been annotated as responsive to LPS in gene ontology. CONCLUSIONS Using weighted gene co-expression network analysis we identified ten co-expressed gene modules significantly regulated by in vitro stimulation with LPS. Apart from 47 genes (5%) all other genes highly interconnected within the most up- and down-regulated modules were also significantly differentially expressed (FDR < 0.05). The LPS-regulated module hub genes have not yet been described as having a role in the immune response to LPS (e.g. VAT1 and TTC25).
Collapse
Affiliation(s)
- Alicja Pacholewska
- Department of Clinical Veterinary Medicine, Swiss Institute of Equine Medicine, Vetsuisse Faculty, University of Bern, and Agroscope, Länggassstrasse 124, 3012, Bern, Switzerland. .,Department of Clinical Research and Veterinary Public Health, Institute of Genetics, Vetsuisse Faculty, University of Bern, Bremgartenstrasse 109A, 3012, Bern, Switzerland.
| | - Eliane Marti
- Department of Clinical Research and Veterinary Public Health, Division of Experimental Clinical Research, Vetsuisse Faculty, University of Bern, Länggassstrasse 124, 3012, Bern, Switzerland
| | - Tosso Leeb
- Department of Clinical Research and Veterinary Public Health, Institute of Genetics, Vetsuisse Faculty, University of Bern, Bremgartenstrasse 109A, 3012, Bern, Switzerland
| | - Vidhya Jagannathan
- Department of Clinical Research and Veterinary Public Health, Institute of Genetics, Vetsuisse Faculty, University of Bern, Bremgartenstrasse 109A, 3012, Bern, Switzerland
| | - Vincent Gerber
- Department of Clinical Veterinary Medicine, Swiss Institute of Equine Medicine, Vetsuisse Faculty, University of Bern, and Agroscope, Länggassstrasse 124, 3012, Bern, Switzerland
| |
Collapse
|
27
|
Ren J, Li Y, Ke H, Li Y, Yang L, Yu H, Huang R, Lu C, Qiu Y. Design, synthesis, and biological evaluation of oxazolidone derivatives as highly potent N-acylethanolamine acid amidase (NAAA) inhibitors. RSC Adv 2017. [DOI: 10.1039/c6ra28734d] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Preventing PEA degradation by inhibition of NAAA is a novel strategy for the treatment of inflammation and pain. We reported the discovery of oxazolidone derivative as highly potent NAAA inhibitors, including 2f, 3h, 3i and 3j.
Collapse
Affiliation(s)
- Jie Ren
- Medical College
- Xiamen University
- Xiamen
- P. R. China
| | - Yuhang Li
- Medical College
- Xiamen University
- Xiamen
- P. R. China
- Xiamen Institute of Rare-earth Materials
| | - Hongwei Ke
- College of Ocean and Earth Science
- Xiamen University
- Xiamen
- P. R. China
| | - Yanting Li
- Medical College
- Xiamen University
- Xiamen
- P. R. China
| | - Longhe Yang
- Engineering Research Center of Marine Biological Resource Comprehensive Utilization
- Third Institute of Oceanography
- State Oceanic Administration
- Xiamen 361005
- P. R. China
| | - Helin Yu
- Medical College
- Xiamen University
- Xiamen
- P. R. China
| | - Rui Huang
- Medical College
- Xiamen University
- Xiamen
- P. R. China
| | - Canzhong Lu
- Xiamen Institute of Rare-earth Materials
- Haixi Institutes
- Chinese Academy of Sciences
- P. R. China
| | - Yan Qiu
- Medical College
- Xiamen University
- Xiamen
- P. R. China
| |
Collapse
|
28
|
Petracca R, Romeo E, Baggelaar MP, Artola M, Pontis S, Ponzano S, Overkleeft HS, van der Stelt M, Piomelli D. Novel activity-based probes for N-acylethanolamine acid amidase. Chem Commun (Camb) 2017; 53:11810-11813. [DOI: 10.1039/c7cc06838g] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Two NAAA activity-based probes were generated as tool for the identification of new inhibitors and the investigation of NAAA physiology.
Collapse
Affiliation(s)
- Rita Petracca
- School of Chemistry and Trinity Biomedical Sciences Institute (TBSI)
- Trinity College Dublin
- The University of Dublin
- Dublin 2
- Ireland
| | - Elisa Romeo
- Drug Discovery and Development
- Istituto Italiano di Tecnologia
- Italy
| | - Marc P. Baggelaar
- Department of Molecular Physiology
- Leiden Institute of Chemistry
- Leiden University
- Leiden
- The Netherlands
| | - Marta Artola
- Department of Bio-organic Synthesis
- Leiden Institute of Chemistry
- Leiden University
- Leiden
- The Netherlands
| | - Silvia Pontis
- Drug Discovery and Development
- Istituto Italiano di Tecnologia
- Italy
| | - Stefano Ponzano
- Drug Discovery and Development
- Istituto Italiano di Tecnologia
- Italy
| | - Herman S. Overkleeft
- Department of Bio-organic Synthesis
- Leiden Institute of Chemistry
- Leiden University
- Leiden
- The Netherlands
| | - Mario van der Stelt
- Department of Molecular Physiology
- Leiden Institute of Chemistry
- Leiden University
- Leiden
- The Netherlands
| | - Daniele Piomelli
- Departments of Anatomy and Neurobiology
- Pharmacology and Biological Chemistry
- University of California
- Irvine
- USA
| |
Collapse
|
29
|
Vago R, Bettiga A, Salonia A, Ciuffreda P, Ottria R. Development of new inhibitors for N-acylethanolamine-hydrolyzing acid amidase as promising tool against bladder cancer. Bioorg Med Chem 2016; 25:1242-1249. [PMID: 28062195 DOI: 10.1016/j.bmc.2016.12.042] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Revised: 12/14/2016] [Accepted: 12/23/2016] [Indexed: 01/01/2023]
Abstract
The endocannabinoid system is a signaling system involved in a wide range of biological effects. Literature strongly suggests the endocannabinoid system role in the pathogenesis of cancer and that its pharmacological activation produces therapeutic benefits. Last research promotes the endocannabinoid system modulation by inhibition of endocannabinoids hydrolytic enzymes instead of direct activation of endocannabinoid receptors to avoid detrimental effects on cognition and motor control. Here we report the identification of N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitors able to reduce cell proliferation and migration and cause cell death on different bladder cancer cell lines. These molecules were designed, synthesized and characterized and active compounds were selected by a fluorescence high-throughput screening method set-up on human recombinant NAAA that also allows to characterize the mechanism of inhibition. Together our results suggest an important role for NAAA in cell migration and in inducing tumor cell death promoting this enzyme as pharmacological target against bladder cancer.
Collapse
Affiliation(s)
- Riccardo Vago
- Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan, Italy; Università Vita-Salute San Raffaele, Via Olgettina 60, Milano, Italy.
| | - Arianna Bettiga
- Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan, Italy.
| | - Andrea Salonia
- Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan, Italy; Università Vita-Salute San Raffaele, Via Olgettina 60, Milano, Italy.
| | - Pierangela Ciuffreda
- Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Via G.B. Grassi 74, Università degli Studi di Milano, Italy.
| | - Roberta Ottria
- Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Via G.B. Grassi 74, Università degli Studi di Milano, Italy.
| |
Collapse
|
30
|
Romeo E, Pontis S, Ponzano S, Bonezzi F, Migliore M, Di Martino S, Summa M, Piomelli D. Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase. J Vis Exp 2016. [PMID: 27911411 DOI: 10.3791/54652] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Activity-based protein profiling (ABPP) is a method for the identification of an enzyme of interest in a complex proteome through the use of a chemical probe that targets the enzyme's active sites. A reporter tag introduced into the probe allows for the detection of the labeled enzyme by in-gel fluorescence scanning, protein blot, fluorescence microscopy, or liquid chromatography-mass spectrometry. Here, we describe the preparation and use of the compound ARN14686, a click chemistry activity-based probe (CC-ABP) that selectively recognizes the enzyme N-acylethanolamine acid amidase (NAAA). NAAA is a cysteine hydrolase that promotes inflammation by deactivating endogenous peroxisome proliferator-activated receptor (PPAR)-alpha agonists such as palmitoylethanolamide (PEA) and oleoylethanolamide (OEA). NAAA is synthesized as an inactive full-length proenzyme, which is activated by autoproteolysis in the acidic pH of the lysosome. Localization studies have shown that NAAA is predominantly expressed in macrophages and other monocyte-derived cells, as well as in B-lymphocytes. We provide examples of how ARN14686 can be used to detect and quantify active NAAA ex vivo in rodent tissues by protein blot and fluorescence microscopy.
Collapse
Affiliation(s)
- Elisa Romeo
- Drug Discovery and Development, Istituto Italiano di Tecnologia
| | - Silvia Pontis
- Drug Discovery and Development, Istituto Italiano di Tecnologia
| | - Stefano Ponzano
- Drug Discovery and Development, Istituto Italiano di Tecnologia
| | - Fabiola Bonezzi
- Drug Discovery and Development, Istituto Italiano di Tecnologia
| | - Marco Migliore
- Drug Discovery and Development, Istituto Italiano di Tecnologia
| | | | - Maria Summa
- Drug Discovery and Development, Istituto Italiano di Tecnologia
| | - Daniele Piomelli
- Drug Discovery and Development, Istituto Italiano di Tecnologia; Departments of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry, University of California, Irvine School of Medicine;
| |
Collapse
|
31
|
Tuo W, Leleu-Chavain N, Spencer J, Sansook S, Millet R, Chavatte P. Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors. J Med Chem 2016; 60:4-46. [DOI: 10.1021/acs.jmedchem.6b00538] [Citation(s) in RCA: 76] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Wei Tuo
- Université de Lille, Inserm, CHU Lille, U995,
LIRIC, Lille Inflammation Research International Center, F-59000 Lille, France
| | - Natascha Leleu-Chavain
- Université de Lille, Inserm, CHU Lille, U995,
LIRIC, Lille Inflammation Research International Center, F-59000 Lille, France
| | - John Spencer
- Department of Chemistry, School of Life Sciences, University of Sussex, Brighton BN1 9QJ, U.K
| | - Supojjanee Sansook
- Department of Chemistry, School of Life Sciences, University of Sussex, Brighton BN1 9QJ, U.K
| | - Régis Millet
- Université de Lille, Inserm, CHU Lille, U995,
LIRIC, Lille Inflammation Research International Center, F-59000 Lille, France
| | - Philippe Chavatte
- Université de Lille, Inserm, CHU Lille, U995,
LIRIC, Lille Inflammation Research International Center, F-59000 Lille, France
| |
Collapse
|
32
|
Avagliano C, Russo R, De Caro C, Cristiano C, La Rana G, Piegari G, Paciello O, Citraro R, Russo E, De Sarro G, Meli R, Mattace Raso G, Calignano A. Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence. Pharmacol Res 2016; 113:276-289. [PMID: 27616549 DOI: 10.1016/j.phrs.2016.09.004] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Revised: 09/05/2016] [Accepted: 09/06/2016] [Indexed: 01/09/2023]
Abstract
Several pathogenetic factors have been involved in the onset and progression of Parkinson's disease (PD), including inflammation, oxidative stress, unfolded protein accumulation, and apoptosis. Palmitoylethanolamide (PEA), an endogenous N-acylethanolamine, has been shown to be a neuroprotective and anti-inflammatory molecule, acting as a peroxisome proliferator activated receptor (PPAR)-α agonist. In this study we investigated the effects of PEA on behavioral alterations and the underlying pathogenic mechanisms in the 6-hydroxydopamine (6-OHDA)-induced model of PD in male mice. Additionally, we showed the involvement of PPAR-α in PEA protective effect on SH-SY5Y neuroblastoma against 6-OHDA damage. Here, we report that PEA (3-30mg/kg/days.c.) improved behavioral impairments induced by unilateral intrastriatal injection of 6-OHDA. This effect was accompanied by a significant increase in tyrosine hydroxylase expression at striatal level, indicating PEA preserving effect on dopaminergic neurons. Moreover, we found a reduction in the expression of pro-inflammatory enzymes, i.e. inducible nitric oxide synthase and cyclooxygenase-2, a modulation between pro- and anti-apoptotic markers, suggestive of PEA capability in controlling neuroinflammation and cell death. Interestingly, PEA also showed protective scavenging effect, through superoxide dismutase induction, and dampened unfolding protein response, interfering on glucose-regulated protein 78 expression and PERK-eIF2α pathway. Similar data were found in in vitro studies, where PEA treatment was found to rescue SH-SY5Y neuroblastoma cells from 6-OHDA-induced damage and death, partly by inhibiting endoplasmic reticulum stress detrimental response. Therefore, PEA, counteracting the pathogenetic aspects involved in the development of PD, showed its therapeutic potential, possibly integrating current treatments correcting dopaminergic deficits and motor dysfunction.
Collapse
Affiliation(s)
- Carmen Avagliano
- Department of Pharmacy, University of Naples "Federico II", 80131, Naples, Italy
| | - Roberto Russo
- Department of Pharmacy, University of Naples "Federico II", 80131, Naples, Italy
| | - Carmen De Caro
- Department of Pharmacy, University of Naples "Federico II", 80131, Naples, Italy
| | - Claudia Cristiano
- Department of Pharmacy, University of Naples "Federico II", 80131, Naples, Italy
| | - Giovanna La Rana
- Department of Pharmacy, University of Naples "Federico II", 80131, Naples, Italy
| | - Giuseppe Piegari
- Department of Veterinary Medicine and Animal Production, University of Naples "Federico II", 80137 Naples, Italy
| | - Orlando Paciello
- Department of Veterinary Medicine and Animal Production, University of Naples "Federico II", 80137 Naples, Italy
| | - Rita Citraro
- Department of Health Sciences, School of Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy
| | - Emilio Russo
- Department of Health Sciences, School of Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy
| | - Giovambattista De Sarro
- Department of Health Sciences, School of Medicine, University of Catanzaro "Magna Graecia", Catanzaro, Italy
| | - Rosaria Meli
- Department of Pharmacy, University of Naples "Federico II", 80131, Naples, Italy
| | | | - Antonio Calignano
- Department of Pharmacy, University of Naples "Federico II", 80131, Naples, Italy
| |
Collapse
|
33
|
Migliore M, Pontis S, Fuentes de Arriba AL, Realini N, Torrente E, Armirotti A, Romeo E, Di Martino S, Russo D, Pizzirani D, Summa M, Lanfranco M, Ottonello G, Busquet P, Jung KM, Garcia-Guzman M, Heim R, Scarpelli R, Piomelli D. Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis. Angew Chem Int Ed Engl 2016. [DOI: 10.1002/ange.201603746] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Marco Migliore
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Silvia Pontis
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Angel Luis Fuentes de Arriba
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Natalia Realini
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Esther Torrente
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Andrea Armirotti
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Elisa Romeo
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Simona Di Martino
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Debora Russo
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Daniela Pizzirani
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Maria Summa
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Massimiliano Lanfranco
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Giuliana Ottonello
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Perrine Busquet
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Kwang-Mook Jung
- Departments of Anatomy and Neurobiology, Pharmacology and Biological Chemistry; University of California; Irvine CA 92697-4625 USA
| | - Miguel Garcia-Guzman
- Anteana Therapeutics; 11189 Sorrento Valley Road, Suite 104 San Diego CA 92121 USA
| | - Roger Heim
- Anteana Therapeutics; 11189 Sorrento Valley Road, Suite 104 San Diego CA 92121 USA
| | - Rita Scarpelli
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
| | - Daniele Piomelli
- Department of Drug Discovery and Development; Fondazione Istituto Italiano di Tecnologia; via Morego 30 16163 Genoa Italy
- Departments of Anatomy and Neurobiology, Pharmacology and Biological Chemistry; University of California; Irvine CA 92697-4625 USA
| |
Collapse
|
34
|
Migliore M, Pontis S, Fuentes de Arriba AL, Realini N, Torrente E, Armirotti A, Romeo E, Di Martino S, Russo D, Pizzirani D, Summa M, Lanfranco M, Ottonello G, Busquet P, Jung KM, Garcia-Guzman M, Heim R, Scarpelli R, Piomelli D. Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis. Angew Chem Int Ed Engl 2016; 55:11193-11197. [PMID: 27404798 DOI: 10.1002/anie.201603746] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Revised: 05/11/2016] [Indexed: 11/11/2022]
Abstract
Palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are endogenous lipid mediators that suppress inflammation. Their actions are terminated by the intracellular cysteine amidase, N-acylethanolamine acid amidase (NAAA). Even though NAAA may offer a new target for anti-inflammatory therapy, the lipid-like structures and reactive warheads of current NAAA inhibitors limit the use of these agents as oral drugs. A series of novel benzothiazole-piperazine derivatives that inhibit NAAA in a potent and selective manner by a non-covalent mechanism are described. A prototype member of this class (8) displays high oral bioavailability, access to the central nervous system (CNS), and strong activity in a mouse model of multiple sclerosis (MS). This compound exemplifies a second generation of non-covalent NAAA inhibitors that may be useful in the treatment of MS and other chronic CNS disorders.
Collapse
Affiliation(s)
- Marco Migliore
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Silvia Pontis
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Angel Luis Fuentes de Arriba
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Natalia Realini
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Esther Torrente
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Andrea Armirotti
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Elisa Romeo
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Simona Di Martino
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Debora Russo
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Daniela Pizzirani
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Maria Summa
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Massimiliano Lanfranco
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Giuliana Ottonello
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Perrine Busquet
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Kwang-Mook Jung
- Departments of Anatomy and Neurobiology, Pharmacology and Biological Chemistry, University of California, Irvine, CA 92697-4625, USA
| | - Miguel Garcia-Guzman
- Anteana Therapeutics, 11189 Sorrento Valley Road, Suite 104, San Diego CA 92121, USA
| | - Roger Heim
- Anteana Therapeutics, 11189 Sorrento Valley Road, Suite 104, San Diego CA 92121, USA
| | - Rita Scarpelli
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Daniele Piomelli
- Department of Drug Discovery and Development, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy.,Departments of Anatomy and Neurobiology, Pharmacology and Biological Chemistry, University of California, Irvine, CA 92697-4625, USA
| |
Collapse
|
35
|
Wilker S, Pfeiffer A, Elbert T, Ovuga E, Karabatsiakis A, Krumbholz A, Thieme D, Schelling G, Kolassa IT. Endocannabinoid concentrations in hair are associated with PTSD symptom severity. Psychoneuroendocrinology 2016; 67:198-206. [PMID: 26923850 DOI: 10.1016/j.psyneuen.2016.02.010] [Citation(s) in RCA: 78] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Revised: 02/11/2016] [Accepted: 02/11/2016] [Indexed: 12/26/2022]
Abstract
The endocannabinoid system has been implicated in the regulation of the stress response, fear memory formation, and inflammatory processes. Posttraumatic stress disorder (PTSD) can result from exposure to extreme stress and is characterized by strong, associative memories for the traumatic events experienced. Furthermore, an elevated physical disease risk has been observed in PTSD, likely to be mediated by inflammatory processes. Therefore, altered endocannabinoid regulation can be expected in individuals with PTSD. However, attempts to assess PTSD-associated differences in the endocannabinoid system from human blood samples have provided inconsistent results, possibly due to fluctuating levels of endocannabinoids. In hair, these neuromodulators are accumulated over time and thus give access to a more stable and reliable assessment. We therefore investigated PTSD-associated differences in hair concentrations of endocannabinoids (N-acyl-ethanolamides palmitoylethanolamide [PEA], oleoylethanolamide [OEA] and stearoylethanolamide [SEA]) in 38 rebel war survivors from Northern Uganda suffering from PTSD and N=38 healthy rebel war survivors without current and lifetime PTSD. PTSD diagnosis and symptom severity were assessed in structured clinical interviews employing the Posttraumatic Diagnostic Scale (PDS). A significant group difference was observed for OEA, with PTSD patients showing reduced hair concentrations. Regression analyses further revealed strong negative relationships between all investigated N-acyl-ethanolamides and symptom severity of PTSD. The observed reductions in endocannabinoids might account for the increased inflammatory state as well as for the failure to extinguish fear memories observed in PTSD. Our findings add to the accumulating evidence suggesting the endocannabinoid system as a target for pharmacological enhancement of exposure-based psychotherapy for PTSD.
Collapse
Affiliation(s)
- Sarah Wilker
- Clinical & Biological Psychology, Institute of Psychology & Education, Ulm University, Albert-Einstein-Allee 47, 89069 Ulm, Germany.
| | - Anett Pfeiffer
- Clinical Psychology, University of Konstanz, Universitätsstr. 10, 78457 Konstanz, Germany
| | - Thomas Elbert
- Clinical Psychology, University of Konstanz, Universitätsstr. 10, 78457 Konstanz, Germany
| | - Emilio Ovuga
- Faculty of Medicine, Gulu University, P.O. Box 166, Gulu, Uganda
| | - Alexander Karabatsiakis
- Clinical & Biological Psychology, Institute of Psychology & Education, Ulm University, Albert-Einstein-Allee 47, 89069 Ulm, Germany
| | - Aniko Krumbholz
- Institute of Doping Analysis and Sports Biochemistry Dresden, 01731 Kreischa, Germany
| | - Detlef Thieme
- Institute of Doping Analysis and Sports Biochemistry Dresden, 01731 Kreischa, Germany
| | - Gustav Schelling
- Department of Anaesthesiology, Ludwig-Maximilians University, 82131 Munich, Germany
| | - Iris-Tatjana Kolassa
- Clinical & Biological Psychology, Institute of Psychology & Education, Ulm University, Albert-Einstein-Allee 47, 89069 Ulm, Germany
| |
Collapse
|
36
|
Patent highlights October–November 2015. Pharm Pat Anal 2016. [DOI: 10.4155/ppa.15.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical R&D.
Collapse
|
37
|
Nuzzi A, Fiasella A, Ortega JA, Pagliuca C, Ponzano S, Pizzirani D, Bertozzi SM, Ottonello G, Tarozzo G, Reggiani A, Bandiera T, Bertozzi F, Piomelli D. Potent α-amino-β-lactam carbamic acid ester as NAAA inhibitors. Synthesis and structure–activity relationship (SAR) studies. Eur J Med Chem 2016; 111:138-59. [DOI: 10.1016/j.ejmech.2016.01.046] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Revised: 01/18/2016] [Accepted: 01/24/2016] [Indexed: 12/23/2022]
|
38
|
Cani PD, Plovier H, Van Hul M, Geurts L, Delzenne NM, Druart C, Everard A. Endocannabinoids--at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol 2016; 12:133-43. [PMID: 26678807 DOI: 10.1038/nrendo.2015.211] [Citation(s) in RCA: 243] [Impact Index Per Article: 30.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Various metabolic disorders are associated with changes in inflammatory tone. Among the latest advances in the metabolism field, the discovery that gut microorganisms have a major role in host metabolism has revealed the possibility of a plethora of associations between gut bacteria and numerous diseases. However, to date, few mechanisms have been clearly established. Accumulating evidence indicates that the endocannabinoid system and related bioactive lipids strongly contribute to several physiological processes and are a characteristic of obesity, type 2 diabetes mellitus and inflammation. In this Review, we briefly define the gut microbiota as well as the endocannabinoid system and associated bioactive lipids. We discuss existing literature regarding interactions between gut microorganisms and the endocannabinoid system, focusing specifically on the triad of adipose tissue, gut bacteria and the endocannabinoid system in the context of obesity and the development of fat mass. We highlight gut-barrier function by discussing the role of specific factors considered to be putative 'gate keepers' or 'gate openers', and their role in the gut microbiota-endocannabinoid system axis. Finally, we briefly discuss data related to the different pharmacological strategies currently used to target the endocannabinoid system, in the context of cardiometabolic disorders and intestinal inflammation.
Collapse
Affiliation(s)
- Patrice D Cani
- Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Avenue E. Mounier 73, Box B1.73.11, Brussels B-1200, Belgium
| | - Hubert Plovier
- Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Avenue E. Mounier 73, Box B1.73.11, Brussels B-1200, Belgium
| | - Matthias Van Hul
- Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Avenue E. Mounier 73, Box B1.73.11, Brussels B-1200, Belgium
| | - Lucie Geurts
- Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Avenue E. Mounier 73, Box B1.73.11, Brussels B-1200, Belgium
| | - Nathalie M Delzenne
- Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Avenue E. Mounier 73, Box B1.73.11, Brussels B-1200, Belgium
| | - Céline Druart
- Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Avenue E. Mounier 73, Box B1.73.11, Brussels B-1200, Belgium
| | - Amandine Everard
- Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Avenue E. Mounier 73, Box B1.73.11, Brussels B-1200, Belgium
| |
Collapse
|
39
|
Abstract
In this review, I will consider the dual nature of Cannabis and cannabinoids. The duality arises from the potential and actuality of cannabinoids in the laboratory and clinic and the 'abuse' of Cannabis outside the clinic. The therapeutic areas currently best associated with exploitation of Cannabis-related medicines include pain, epilepsy, feeding disorders, multiple sclerosis and glaucoma. As with every other medicinal drug of course, the 'trick' will be to maximise the benefit and minimise the cost. After millennia of proximity and exploitation of the Cannabis plant, we are still playing catch up with an understanding of its potential influence for medicinal benefit.
Collapse
Affiliation(s)
- Stephen P H Alexander
- Life Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, England, United Kingdom.
| |
Collapse
|
40
|
Abstract
N-acylethanolamine-hydrolyzing acid amidase (NAAA) is a lysosomal hydrolase degrading various N-acylethanolamines at acidic pH. Since NAAA prefers anti-inflammatory and analgesic palmitoylethanolamide to other N-acylethanolamines as a substrate, its specific inhibitors are expected as a new class of anti-inflammatory and analgesic agents. Here, we introduce an NAAA assay system, using [(14)C]palmitoylethanolamide and thin-layer chromatography. The preparation of NAAA enzyme from native and recombinant sources as well as the chemical synthesis of N-[1'-(14)C]palmitoyl-ethanolamine is also described.
Collapse
Affiliation(s)
- Kazuhito Tsuboi
- Department of Biochemistry, Kagawa University School of Medicine, 1750-1 Ikenobe, Miki, Kagawa, 761-0793, Japan
| | - Natsuo Ueda
- Department of Biochemistry, Kagawa University School of Medicine, 1750-1 Ikenobe, Miki, Kagawa, 761-0793, Japan.
| |
Collapse
|
41
|
Pontis S, Ribeiro A, Sasso O, Piomelli D. Macrophage-derived lipid agonists of PPAR-αas intrinsic controllers of inflammation. Crit Rev Biochem Mol Biol 2015; 51:7-14. [DOI: 10.3109/10409238.2015.1092944] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
42
|
Rivera P, Blanco E, Bindila L, Alen F, Vargas A, Rubio L, Pavón FJ, Serrano A, Lutz B, Rodríguez de Fonseca F, Suárez J. Pharmacological activation of CB2 receptors counteracts the deleterious effect of ethanol on cell proliferation in the main neurogenic zones of the adult rat brain. Front Cell Neurosci 2015; 9:379. [PMID: 26483633 PMCID: PMC4587308 DOI: 10.3389/fncel.2015.00379] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2015] [Accepted: 09/11/2015] [Indexed: 11/13/2022] Open
Abstract
Chronic alcohol exposure reduces endocannabinoid activity and disrupts adult neurogenesis in rodents, which results in structural and functional alterations. Cannabinoid receptor agonists promote adult neural progenitor cell (NPC) proliferation. We evaluated the protective effects of the selective CB1 receptor agonist ACEA, the selective CB2 receptor agonist JWH133 and the fatty-acid amide-hydrolase (FAAH) inhibitor URB597, which enhances endocannabinoid receptor activity, on NPC proliferation in rats with forced consumption of ethanol (10%) or sucrose liquid diets for 2 weeks. We performed immunohistochemical and stereological analyses of cells expressing the mitotic phosphorylation of histone-3 (phospho-H3+) and the replicating cell DNA marker 5-bromo-2'-deoxyuridine (BrdU+) in the main neurogenic zones of adult brain: subgranular zone of dentate gyrus (SGZ), subventricular zone of lateral ventricles (SVZ) and hypothalamus. Animals were allowed ad libitum ethanol intake (7.3 ± 1.1 g/kg/day) after a controlled isocaloric pair-feeding period of sucrose and alcoholic diets. Alcohol intake reduced the number of BrdU+ cells in SGZ, SVZ, and hypothalamus. The treatments (URB597, ACEA, JWH133) exerted a differential increase in alcohol consumption over time, but JWH133 specifically counteracted the deleterious effect of ethanol on NPC proliferation in the SVZ and SGZ, and ACEA reversed this effect in the SGZ only. JWH133 also induced an increased number of BrdU+ cells expressing neuron-specific β3-tubulin in the SVZ and SGZ. These results indicated that the specific activation of CB2 receptors rescued alcohol-induced impaired NPC proliferation, which is a potential clinical interest for the risk of neural damage in alcohol dependence.
Collapse
Affiliation(s)
- Patricia Rivera
- UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain
| | - Eduardo Blanco
- UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain ; Departament de Pedagogia i Psicologia, Facultat de Ciències de l'Educació, Universitat de Lleida Lleida, Spain
| | - Laura Bindila
- Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg-University of Mainz Mainz, Germany
| | - Francisco Alen
- UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain
| | - Antonio Vargas
- UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain
| | - Leticia Rubio
- Departamento de Anatomía y Medicina Legal, Universidad de Málaga Málaga, Spain
| | - Francisco J Pavón
- UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain
| | - Antonia Serrano
- UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain
| | - Beat Lutz
- Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg-University of Mainz Mainz, Germany
| | - Fernando Rodríguez de Fonseca
- UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain
| | - Juan Suárez
- UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain
| |
Collapse
|
43
|
Romeo E, Ponzano S, Armirotti A, Summa M, Bertozzi F, Garau G, Bandiera T, Piomelli D. Activity-Based Probe for N-Acylethanolamine Acid Amidase. ACS Chem Biol 2015; 10:2057-2064. [PMID: 26102511 DOI: 10.1021/acschembio.5b00197] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
N-Acylethanolamine acid amidase (NAAA) is a lysosomal cysteine hydrolase involved in the degradation of saturated and monounsaturated fatty acid ethanolamides (FAEs), a family of endogenous lipid signaling molecules that includes oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). Among the reported NAAA inhibitors, α-amino-β-lactone (3-aminooxetan-2-one) derivatives have been shown to prevent FAE hydrolysis in innate-immune and neural cells and to reduce reactions to inflammatory stimuli. Recently, we disclosed two potent and selective NAAA inhibitors, the compounds ARN077 (5-phenylpentyl-N-[(2S,3R)-2-methyl-4-oxo-oxetan-3-yl]carbamate) and ARN726 (4-cyclohexylbutyl-N-[(S)-2-oxoazetidin-3-yl]carbamate). The former is active in vivo by topical administration in rodent models of hyperalgesia and allodynia, while the latter exerts systemic anti-inflammatory effects in mouse models of lung inflammation. In the present study, we designed and validated a derivative of ARN726 as the first activity-based protein profiling (ABPP) probe for the in vivo detection of NAAA. The newly synthesized molecule 1 is an effective in vitro and in vivo click-chemistry activity based probe (ABP), which is able to capture the catalytically active form of NAAA in Human Embryonic Kidney 293 (HEK293) cells overexpressing human NAAA as well as in rat lung tissue. Competitive ABPP with 1 confirmed that ARN726 and ARN077 inhibit NAAA in vitro and in vivo. Compound 1 is a useful new tool to identify activated NAAA both in vitro and in vivo and to investigate the physiological and pathological roles of this enzyme.
Collapse
Affiliation(s)
- Elisa Romeo
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Stefano Ponzano
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Andrea Armirotti
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Maria Summa
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Fabio Bertozzi
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Gianpiero Garau
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Tiziano Bandiera
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Daniele Piomelli
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
- Departments
of Anatomy and Neurobiology, Pharmacology, and Biological Chemistry, University of California, 3216 Gillespie Neuroscience Facility, Irvine, California 92697-4621, United States
| |
Collapse
|
44
|
Lowin T, Straub RH. Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis. Arthritis Res Ther 2015; 17:226. [PMID: 26343051 PMCID: PMC4561168 DOI: 10.1186/s13075-015-0743-x] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Chronic inflammation in rheumatoid arthritis (RA) is accompanied by activation of the sympathetic nervous system, which can support the immune system to perpetuate inflammation. Several animal models of arthritis already demonstrated a profound influence of adrenergic signaling on the course of RA. Peripheral norepinephrine release from sympathetic terminals is controlled by cannabinoid receptor type 1 (CB1), which is activated by two major endocannabinoids (ECs), arachidonylethanolamine (anandamide) and 2-arachidonylglycerol. These ECs also modulate function of transient receptor potential channels (TRPs) located on sensory nerve fibers, which are abundant in arthritic synovial tissue. TRPs not only induce the sensation of pain but also support inflammation via secretion of pro-inflammatory neuropeptides. In addition, many cell types in synovial tissue express CB1 and TRPs. In this review, we focus on CB1 and transient receptor potential vanilloid 1 (TRPV1)-mediated effects on RA since most anti-inflammatory mechanisms induced by cannabinoids are attributed to cannabinoid receptor type 2 (CB2) activation. We demonstrate how CB1 agonism or antagonism can modulate arthritic disease. The concept of functional antagonism with continuous CB1 activation is discussed. Since fatty acid amide hydrolase (FAAH) is a major EC-degrading enzyme, the therapeutic possibility of FAAH inhibition is studied. Finally, the therapeutic potential of ECs is examined since they interact with cannabinoid receptors and TRPs but do not produce central side effects.
Collapse
Affiliation(s)
- Torsten Lowin
- Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, University Hospital of Regensburg, D-93053, Regensburg, Germany.
| | - Rainer H Straub
- Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, University Hospital of Regensburg, D-93053, Regensburg, Germany
| |
Collapse
|
45
|
Fatty acids, endocannabinoids and inflammation. Eur J Pharmacol 2015; 785:96-107. [PMID: 26325095 DOI: 10.1016/j.ejphar.2015.08.051] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Revised: 07/01/2015] [Accepted: 08/26/2015] [Indexed: 01/08/2023]
Abstract
From their phylogenetic and pharmacological classification it might be inferred that cannabinoid receptors and their endogenous ligands constitute a rather specialised and biologically distinct signalling system. However, the opposite is true and accumulating data underline how much the endocannabinoid system is intertwined with other lipid and non-lipid signalling systems. Endocannabinoids per se have many structural congeners, and these molecules exist in dynamic equilibria with different other lipid-derived mediators, including eicosanoids and prostamides. With multiple crossroads and shared targets, this creates a versatile system involved in fine-tuning different physiological and metabolic processes, including inflammation. A key feature of this 'expanded' endocannabinoid system, or 'endocannabinoidome', is its subtle orchestration based on interactions between a relatively small number of receptors and multiple ligands with different but partly overlapping activities. Following an update on the role of the 'endocannabinoidome' in inflammatory processes, this review continues with possible targets for intervention at the level of receptors or enzymes involved in formation or breakdown of endocannabinoids and their congeners. Although its pleiotropic character poses scientific challenges, the 'expanded' endocannabinoid system offers several opportunities for prevention and therapy of chronic diseases. In this respect, successes are more likely to come from 'multiple-target' than from 'single-target' strategies.
Collapse
|
46
|
Potential analgesic effects of a novel N-acylethanolamine acid amidase inhibitor F96 through PPAR-α. Sci Rep 2015; 5:13565. [PMID: 26310614 PMCID: PMC4550851 DOI: 10.1038/srep13565] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2015] [Accepted: 07/30/2015] [Indexed: 01/01/2023] Open
Abstract
Pharmacological blockade of N-acylethanolamine acid amidase (NAAA) activity is an available approach for inflammation and pain control through restoring the ability of endogenous PEA. But the recently reported NAAA inhibitors suffer from the chemical and biological unstable properties, which restrict functions of NAAA inhibition in vivo. It is still unrevealed whether systematic inhibition of NAAA could modulate PEA-mediated pain signalings. Here we reported an oxazolidinone imide compound 3-(6-phenylhexanoyl) oxazolidin-2-one (F96), which potently and selectively inhibited NAAA activity (IC50 = 270 nM). Intraperitoneal (i.p.) injection of F96 (3–30 mg/kg) dose-dependently reduced ear edema and restored PEA levels of ear tissues in 12-O-Tetradecanoylphorbol-13-acetate (TPA) induced ear edema models. Furthermore, F96 inhibited acetic acid-induced writhing and increased spared nerve injury induced tactile allodynia thresholds in a dose-dependent manner. Pharmacological effects of F96 (10 mg/kg, i.p.) on various animal models were abolished in PPAR-α−/− mice, and were prevented by PPAR-α antagonist MK886 but not by canabinoid receptor type 1 (CB1) antagonist Rimonabant nor canabinoid receptor type 2 (CB2) antagonist SR144528. Zebrafish embryos experiments showed better security and lower toxicity for F96 than ibuprofen. These results revealed that F96 might be useful in treating inflammatory and neuropathic pain by NAAA inhibition depending on PPAR-α receptors.
Collapse
|
47
|
Ribeiro A, Pontis S, Mengatto L, Armirotti A, Chiurchiù V, Capurro V, Fiasella A, Nuzzi A, Romeo E, Moreno-Sanz G, Maccarrone M, Reggiani A, Tarzia G, Mor M, Bertozzi F, Bandiera T, Piomelli D. A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation. ACS Chem Biol 2015; 10:1838-46. [PMID: 25874594 DOI: 10.1021/acschembio.5b00114] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Fatty acid ethanolamides such as palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are lipid-derived mediators that potently inhibit pain and inflammation by ligating type-α peroxisome proliferator-activated receptors (PPAR-α). These bioactive substances are preferentially degraded by the cysteine hydrolase, N-acylethanolamine acid amidase (NAAA), which is highly expressed in macrophages. Here, we describe a new class of β-lactam derivatives that are potent, selective, and systemically active inhibitors of intracellular NAAA activity. The prototype of this class deactivates NAAA by covalently binding the enzyme's catalytic cysteine and exerts profound anti-inflammatory effects in both mouse models and human macrophages. This agent may be used to probe the functions of NAAA in health and disease and as a starting point to discover better anti-inflammatory drugs.
Collapse
Affiliation(s)
- Alison Ribeiro
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, via Morego
30, 16163 Genoa, Italy
| | - Silvia Pontis
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, via Morego
30, 16163 Genoa, Italy
| | - Luisa Mengatto
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, via Morego
30, 16163 Genoa, Italy
| | - Andrea Armirotti
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, via Morego
30, 16163 Genoa, Italy
| | - Valerio Chiurchiù
- European
Center for Brain Research, Fondazione Santa Lucia, via del Fosso
di Fiorano 64/65, 00143 Rome, Italy
| | - Valeria Capurro
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, via Morego
30, 16163 Genoa, Italy
| | - Annalisa Fiasella
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, via Morego
30, 16163 Genoa, Italy
| | - Andrea Nuzzi
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, via Morego
30, 16163 Genoa, Italy
| | - Elisa Romeo
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, via Morego
30, 16163 Genoa, Italy
| | - Guillermo Moreno-Sanz
- Department
of Anatomy and Neurobiology, University of California, Irvine, California 92697-4625, United States
| | - Mauro Maccarrone
- Department
of Anatomy and Neurobiology, University of California, Irvine, California 92697-4625, United States
- Campus Bio-Medico University of Rome, via Alvaro del Portillo 21, 00128, Rome, Italy
| | - Angelo Reggiani
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, via Morego
30, 16163 Genoa, Italy
| | - Giorgio Tarzia
- Department
of Biomolecular Science, University of Urbino “Carlo Bo”, 61029 Urbino, Italy
| | - Marco Mor
- Pharmaceutical
Department, University of Parma, I-43100 Parma, Italy
| | - Fabio Bertozzi
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, via Morego
30, 16163 Genoa, Italy
| | - Tiziano Bandiera
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, via Morego
30, 16163 Genoa, Italy
| | - Daniele Piomelli
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, via Morego
30, 16163 Genoa, Italy
- Departments
of Anatomy and Neurobiology, Pharmacology and Biological Chemistry, University of California, Irvine, California 92697, United States
| |
Collapse
|
48
|
Mofford DM, Adams ST, Reddy GSKK, Reddy GR, Miller SC. Luciferin Amides Enable in Vivo Bioluminescence Detection of Endogenous Fatty Acid Amide Hydrolase Activity. J Am Chem Soc 2015; 137:8684-7. [PMID: 26120870 PMCID: PMC4507478 DOI: 10.1021/jacs.5b04357] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
![]()
Firefly luciferase is homologous
to fatty acyl-CoA synthetases.
We hypothesized that the firefly luciferase substrate d-luciferin
and its analogs are fatty acid mimics that are ideally suited to probe
the chemistry of enzymes that release fatty acid products. Here, we
synthesized luciferin amides and found that these molecules are hydrolyzed
to substrates for firefly luciferase by the enzyme fatty acid amide
hydrolase (FAAH). In the presence of luciferase, these molecules enable
highly sensitive and selective bioluminescent detection of FAAH activity in vitro, in live cells, and in vivo. The
potency and tissue distribution of FAAH inhibitors can be imaged in
live mice, and luciferin amides serve as exemplary reagents for greatly
improved bioluminescence imaging in FAAH-expressing tissues such as
the brain.
Collapse
Affiliation(s)
- David M Mofford
- Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Spencer T Adams
- Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, United States
| | - G S Kiran Kumar Reddy
- Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Gadarla Randheer Reddy
- Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, United States
| | - Stephen C Miller
- Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, United States
| |
Collapse
|
49
|
Rivera P, Bindila L, Pastor A, Pérez-Martín M, Pavón FJ, Serrano A, de la Torre R, Lutz B, Rodríguez de Fonseca F, Suárez J. Pharmacological blockade of the fatty acid amide hydrolase (FAAH) alters neural proliferation, apoptosis and gliosis in the rat hippocampus, hypothalamus and striatum in a negative energy context. Front Cell Neurosci 2015; 9:98. [PMID: 25870539 PMCID: PMC4375993 DOI: 10.3389/fncel.2015.00098] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2014] [Accepted: 03/05/2015] [Indexed: 11/13/2022] Open
Abstract
Endocannabinoids participate in the control of neurogenesis, neural cell death and gliosis. The pharmacological effect of the fatty acid amide hydrolase (FAAH) inhibitor URB597, which limits the endocannabinoid degradation, was investigated in the present study. Cell proliferation (phospho-H3+ or BrdU+ cells) of the main adult neurogenic zones as well as apoptosis (cleaved caspase-3+), astroglia (GFAP+), and microglia (Iba1+ cells) were analyzed in the hippocampus, hypothalamus and striatum of rats intraperitoneally treated with URB597 (0.3 mg/kg/day) at one dose/4-days resting or 5 doses (1 dose/day). Repeated URB597 treatment increased the plasma levels of the N-acylethanolamines oleoylethanolamide, palmitoylethanolamide and arachidonoylethanolamine, reduced the plasma levels of glucose, triglycerides and cholesterol, and induced a transitory body weight decrease. The hippocampi of repeated URB597-treated rats showed a reduced number of phospho-H3+ and BrdU+ subgranular cells as well as GFAP+, Iba1+ and cleaved caspase-3+ cells, which was accompanied with decreased hippocampal expression of the cannabinoid CB1 receptor gene Cnr1 and Faah. In the hypothalami of these rats, the number of phospho-H3+, GFAP+ and 3-weeks-old BrdU+ cells was specifically decreased. The reduced striatal expression of CB1 receptor in repeated URB597-treated rats was only associated with a reduced apoptosis. In contrast, the striatum of acute URB597-treated rats showed an increased number of subventricular proliferative, astroglial and apoptotic cells, which was accompanied with increased Faah expression. Main results indicated that FAAH inhibitor URB597 decreased neural proliferation, glia and apoptosis in a brain region-dependent manner, which were coupled to local changes in Faah and/or Cnr1 expression and a negative energy context.
Collapse
Affiliation(s)
- Patricia Rivera
- UGC Salud Mental, Instituto de Investigación Biomédica (IBIMA), Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain ; CIBER OBN, Instituto de Salud Carlos III Madrid, Spain
| | - Laura Bindila
- Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg-University of Mainz Mainz, Germany
| | - Antoni Pastor
- Institut Hospital del Mar d'Investigacions Mediques Barcelona, Spain ; Facultat de Medicina, Universitat Autonoma de Barcelona Barcelona, Spain
| | - Margarita Pérez-Martín
- Departamento de Biología Celular, Genética y Fisiología, Instituto de Investigación Biomédica (IBIMA), Universidad de Málaga Málaga, Spain
| | - Francisco J Pavón
- UGC Salud Mental, Instituto de Investigación Biomédica (IBIMA), Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain ; CIBER OBN, Instituto de Salud Carlos III Madrid, Spain
| | - Antonia Serrano
- UGC Salud Mental, Instituto de Investigación Biomédica (IBIMA), Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain ; CIBER OBN, Instituto de Salud Carlos III Madrid, Spain
| | - Rafael de la Torre
- CIBER OBN, Instituto de Salud Carlos III Madrid, Spain ; Institut Hospital del Mar d'Investigacions Mediques Barcelona, Spain ; Facultat de Ciencies de la Salut i de la Vida, Universitat Pompeu Fabra (CEXS-UPF) Barcelona, Spain
| | - Beat Lutz
- Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg-University of Mainz Mainz, Germany
| | - Fernando Rodríguez de Fonseca
- UGC Salud Mental, Instituto de Investigación Biomédica (IBIMA), Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain ; CIBER OBN, Instituto de Salud Carlos III Madrid, Spain
| | - Juan Suárez
- UGC Salud Mental, Instituto de Investigación Biomédica (IBIMA), Universidad de Málaga-Hospital Universitario Regional de Málaga Málaga, Spain ; CIBER OBN, Instituto de Salud Carlos III Madrid, Spain
| |
Collapse
|
50
|
Ponzano S, Berteotti A, Petracca R, Vitale R, Mengatto L, Bandiera T, Cavalli A, Piomelli D, Bertozzi F, Bottegoni G. Synthesis, Biological Evaluation, and 3D QSAR Study of 2-Methyl-4-oxo-3-oxetanylcarbamic Acid Esters as N-Acylethanolamine Acid Amidase (NAAA) Inhibitors. J Med Chem 2014; 57:10101-11. [DOI: 10.1021/jm501455s] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Stefano Ponzano
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Anna Berteotti
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Rita Petracca
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Romina Vitale
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Luisa Mengatto
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Tiziano Bandiera
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Andrea Cavalli
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
- Department
of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro
6, I-40126 Bologna, Italy
| | - Daniele Piomelli
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
- Department
of Anatomy and Neurobiology, Department of
Pharmacology, and Department of Biological
Chemistry, University of California—Irvine, Irvine, California 92697-4621, United States
| | - Fabio Bertozzi
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| | - Giovanni Bottegoni
- Drug
Discovery and Development, Istituto Italiano di Tecnologia, Via Morego
30, I-16163 Genova, Italy
| |
Collapse
|